Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 16:04 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update

– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo® –– First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 –– Work...
July 28, 2020 09:00 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide...
July 22, 2020 08:30 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Names James Huang to Board of Directors

– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech –– Managing Partner at Kleiner Perkins...
July 09, 2020 16:15 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas

BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific...
July 08, 2020 08:30 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has...
June 22, 2020 08:00 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma

BOSTON, June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial...
June 15, 2020 08:00 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board

BOSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl...
June 12, 2020 09:00 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020

BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...
May 29, 2020 08:00 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology

– Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile – – Controlled IL-12 in combination with PD-1...
May 27, 2020 16:15 ET | Source: ZIOPHARM Oncology Inc

Ziopharm Oncology Announces Management Transition

BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr. Mauney remains a...